Clofazimine Is a Novel Inhibitor of Human Kv1.3 Potassium Channel and Calcium Signaling in T Lymphocytes

Yunzhao R. REN1,2, Fan PAN1, Suhel PARVEZ3, Andrea FLEIG3, Curtis R. CHONG1, Jing XU1, Yongjun DANG1, Jin ZHANG1, Hongsi JIANG4, Reinhold PENNER3, Jun O. LIU1,2,5,*

1Department of Pharmacology and Molecular Sciences, 2Program in Biochemistry, Cellular and Molecular Biology, 5Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 3Center for Biomedical Research at The Queen’s Medical Center and John A. Burns School of Medicine at the University of Hawaii, Honolulu, Hawaii, USA; 4Department of Medicine, Feinberg School of Medicine, Northwestern University, Evanston, Illinois, USA
*E-mail: joliu@jhu.edu

The Kv1.3 potassium channel plays an essential role in effector memory T cells and has been implicated in a number of important autoimmune diseases including multiple sclerosis, psoriasis and type 1 diabetes. A number of potent small molecule inhibitors of Kv1.3 channel have been reported, some of which were found to be effective in various animal models of autoimmune diseases. We report herein the identification of clofazimine, a known anti-mycobacterial drug, as a novel inhibitor of human Kv1.3. Clofazimine was initially identified as an inhibitor of intracellular T cell receptor-mediated signaling leading to the activation of transcription of human interleukin-2 gene in T cells from a screen of the Johns Hopkins Drug Library. A systematic mechanistic deconvolution revealed that clofazimine selectively blocked the Kv1.3 channel activity, thus perturbing the oscillation frequency of the calcium-release activated calcium channel, which in turn led to the inhibition of the calcineurin-NFAT signaling pathway. Importantly, clofazimine was found to be effective in blocking human T cell-mediated skin graft rejection in an animal model in vivo. Together, these observations suggest that clofazimine is a promising immunomodulatory drug candidate for treating a variety of autoimmune disorders.